Synthesis and biological evaluation of 2-arylbenzofuran derivatives as potential anti-Alzheimer’s disease agents
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 36 (1) , 1345-1355
Abstract
Alzheimer's disease (AD) is a type of progressive dementia caused by degeneration of the nervous system. A single target drug usually does not work well. Therefore, multi-target drugs are designed and developed so that one drug can specifically bind to multiple targets to ensure clinical effectiveness and reduce toxicity. We synthesised a series of 2-arylbenzofuran derivatives and evaluated their in vitro activities. 2-Arylbenzofuran compounds have good dual cholinesterase inhibitory activity and β-secretase inhibitory activity. The IC50 value of compound 20 against acetylcholinesterase inhibition (0.086 ± 0.01 µmol·L−1) is similar to donepezil (0.085 ± 0.01 µmol·L−1) and is better than baicalein (0.404 ± 0.04 µmol·L−1). And most of the compounds have good BACE1 inhibitory activity, of which 3 compounds (8, 19 and 20) show better activity than baicalein (0.087 ± 0.03 µmol·L−1). According to experimental results, 2-arylbenzofuran compounds provide an idea for drug design to develop prevention and treatment for AD.Keywords
This publication has 33 references indexed in Scilit:
- 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agentsEuropean Journal of Medicinal Chemistry, 2012
- Biochemistry of Amyloid -Protein and Amyloid Deposits in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Synthesis and antimicrobial evaluation of new benzofuran derivativesEuropean Journal of Medicinal Chemistry, 2011
- The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Intramembrane Proteolysis by γ-SecretaseJournal of Biological Chemistry, 2008
- Antimicrobial Activities of Hydrophobic 2-Arylbenzofurans and an Isoflavone against Vancomycin-Resistant Enterococci and Methicillin-ResistantStaphylococcus aureusPlanta Medica, 2004
- Neurobiology of butyrylcholinesteraseNature Reviews Neuroscience, 2003
- A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to ButyrylcholinesteraseCurrent Medical Research and Opinion, 2001
- β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACEScience, 1999
- Two New 2-Arylbenzofuran Derivatives from Hypoglycemic Activity-Bearing Fractions of Morus insignis.Chemical and Pharmaceutical Bulletin, 1993